Evidence map›Paper›PMID 36546783›Full record

ArticleNucleic acids research2023

Insights into the molecular mechanism of translation inhibition by the ribosome-targeting antibiotic thermorubin.

Madhura N Paranjpe, Valeria I Marina, Aleksandr A Grachev, Tinashe P Maviza, Olga A Tolicheva, Alena Paleskava, Ilya A Osterman, Petr V Sergiev, Andrey L Konevega, Yury S Polikanov and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Approaches for Studying Context Specificity of Translation Inhibitor Action.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Development of 2nd generation aminomethyl spectinomycins that overcome native efflux inProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Madhura N ParanjpeDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Valeria I MarinaDepartment of Chemistry and Institute of Functional Genomics, Lomonosov Moscow State University, Moscow 119992, Russia.
Aleksandr A GrachevPeter the Great St.Petersburg Polytechnic University, Saint Petersburg 195251, Russia.
Tinashe P MavizaDepartment of Chemistry and Institute of Functional Genomics, Lomonosov Moscow State University, Moscow 119992, Russia.
Olga A TolichevaPeter the Great St.Petersburg Polytechnic University, Saint Petersburg 195251, Russia.
Alena PaleskavaPeter the Great St.Petersburg Polytechnic University, Saint Petersburg 195251, Russia.
Ilya A OstermanDepartment of Chemistry and Institute of Functional Genomics, Lomonosov Moscow State University, Moscow 119992, Russia.
Petr V SergievDepartment of Chemistry and Institute of Functional Genomics, Lomonosov Moscow State University, Moscow 119992, Russia.
Andrey L KonevegaPeter the Great St.Petersburg Polytechnic University, Saint Petersburg 195251, Russia.ORCID 0000-0003-0125-7150
Yury S PolikanovDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-5064-0327
Matthieu G GagnonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX77555, USA.ORCID 0000-0003-4516-604X
Lomonosov Moscow State University · RUPeter the Great St. Petersburg Polytechnic University · RUUniversity of Illinois Chicago · USThe University of Texas Medical Branch at Galveston · US

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Structural Basis for the Allosteric Mechanisms Regulating Ribosome FunctionR01GM136936 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GAGNON, MATTHIEU · 2020 to 2024
$1.8M
NIGMS NIH HHS R01 GM136936
6 · The paper itself

Abstract

Thermorubin (THR) is an aromatic anthracenopyranone antibiotic active against both Gram-positive and Gram-negative bacteria. It is known to bind to the 70S ribosome at the intersubunit bridge B2a and was thought to inhibit factor-dependent initiation of translation and obstruct the accommodation of tRNAs into the A site. Here, we show that thermorubin causes ribosomes to stall in vivo and in vitro at internal and termination codons, thereby allowing the ribosome to initiate protein synthesis and translate at least a few codons before stalling. Our biochemical data show that THR affects multiple steps of translation elongation with a significant impact on the binding stability of the tRNA in the A site, explaining premature cessation of translation. Our high-resolution crystal and cryo-EM structures of the 70S-THR complex show that THR can co-exist with P- and A-site tRNAs, explaining how ribosomes can elongate in the presence of the drug. Remarkable is the ability of THR to arrest ribosomes at the stop codons. Our data suggest that by causing structural re-arrangements in the decoding center, THR interferes with the accommodation of tRNAs or release factors into the ribosomal A site.

Indexed as

AnthraquinonesAnti-Bacterial AgentsGram-Negative BacteriaGram-Positive BacteriaProtein BiosynthesisCodon, TerminatorRibosomesAnthraquinonesAnti-Bacterial AgentsCodon, Terminatorthermorubin

Identifiers

PMID36546783
PMCPMC9841432
OpenAlexW4312191747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.